Linklaters advises Fareva on its acquisition of majority stake in Sanofi’s Lüleburgaz manufacturing facility

Linklaters has advised Fareva, a world leader in industrial subcontracting for the pharmaceuticals, cosmetics, and industrial & household sectors, on its entry into a share purchase agreement with Sanofi to acquire a 70% stake in the company operating Sanofi’s pharmaceutical manufacturing facility in Lüleburgaz, Turkey. Sanofi will retain a 30% minority stake in the company. 

Completion of the transaction is subject to customary regulatory approvals, including clearance from the Turkish Competition Authority.

 The Linklaters team was led by François Kopf, Partner in Restructuring & Insolvency, Julien Bourmaud-Danto, Partner in Corporate M&A, and Sonia Cissé, Partner in Tech & Data and Cybersecurity. 

The team also included Mathilde Gruaz, Associate in Corporate/M&A, Julia Loiseau, Associate in Tech & Data and Cybersecurity, Thomas Elkins, Partner and William Carlier, Associate, in Antitrust & Foreign Investments, Jean-François Merdrignac, Counsel and Marion Delvallet, associate, in Intellectual Property.